Seliciclib (roscovitine or CYC202) is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors that preferentially inhibit multiple …

R-roscovitine (Seliciclib or CYC202) is a cyclin-dependent kinase (CDK) inhibitor that preferentially inhibits multiple enzyme targets including CDK2, CDK7 and CDK9, which alter …

Roscovitine [CY-202, (R)-Roscovitine, Seliciclib] is a small molecule that inhibits cyclin-dependent kinases (CDKs) through direct competition at the ATP-binding site. It is a broad-range purine …

Nov 23, 2021 · Roscovitine shows increased selectivity for Cdk5 over other Cdks, and it is the most widely studied Cdk5 inhibitor in the field. The IC 50 of roscovitine for Cdk5/p25 complex …

R-roscovitine (Seliciclib or CYC202) is a cyclin-dependent kinase (CDK) inhibitor that preferentially inhibits multiple enzyme targets including CDK2, CDK7 and CDK9, which alter …

We have investigated the selectivity of (R)-roscovitine using three different methods: 1) testing on a wide panel of purified kinases that, along with previously published data, now reaches 151 …

Studies have shown that roscovitine affects the cell cycle by reducing the phosphorylation of Rb. On the other side, roscovitine regulates RNA Pol II phosphorylation by CDK7 inhibition and …

Jan 15, 1997 · Through its unique selectivity for some cyclin-dependent kinases, roscovitine provides a useful antimitotic reagent for cell cycle studies and may prove interesting to control …

Roscovitine reduces the degree of activation of Cdk5 and decreases the abnormal phosphorylation. Cdk5 is also associated with excitotoxicity, and roscovitine may decrease …

Roscovitine exerts a tumor suppressive effect on endocrine-resistant breast cancer xenografts. Nude mice were subcutaneously injected with the endocrine-resistant model cells (a) MCF7 …